Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Receivables - Net (2020 - 2023)

Historic Receivables - Net for Barinthus Biotherapeutics (BRNS) over the last 4 years, with Q1 2023 value amounting to $172000.0.

  • Barinthus Biotherapeutics' Receivables - Net fell 9904.5% to $172000.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $172000.0, marking a year-over-year decrease of 9904.5%. This contributed to the annual value of $5.5 million for FY2022, which is 2752000.0% up from last year.
  • Per Barinthus Biotherapeutics' latest filing, its Receivables - Net stood at $172000.0 for Q1 2023, which was down 9904.5% from $5.5 million recorded in Q4 2022.
  • In the past 5 years, Barinthus Biotherapeutics' Receivables - Net ranged from a high of $18.0 million in Q1 2022 and a low of $20000.0 during Q4 2021
  • In the last 4 years, Barinthus Biotherapeutics' Receivables - Net had a median value of $172000.0 in 2023 and averaged $2.7 million.
  • Per our database at Business Quant, Barinthus Biotherapeutics' Receivables - Net surged by 2752000.0% in 2022 and then plummeted by 9904.5% in 2023.
  • Barinthus Biotherapeutics' Receivables - Net (Quarter) stood at $518000.0 in 2020, then plummeted by 96.14% to $20000.0 in 2021, then soared by 27520.0% to $5.5 million in 2022, then tumbled by 96.89% to $172000.0 in 2023.
  • Its last three reported values are $172000.0 in Q1 2023, $5.5 million for Q4 2022, and $26000.0 during Q3 2022.